View source for CR:DOI:c605aab953141c2376f3b8840f0d6d24

{{#scite:
 |reference=pawar2019ri
 |type=article-journal
 |title=Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study
 |author=Ajinkya Pawar;Rishi J Desai;Daniel H Solomon;Adrian J Santiago Ortiz;Sara Gale;Min Bao;Khaled Sarsour;Sebastian Schneeweiss;Seoyoung C Kim|+sep=;
 |journal=Annals of the Rheumatic Diseases
 |publisher=BMJ
 |year=2019
 |volume=78
 |issue=4
 |pages=456-464
 |doi=10.1136/annrheumdis-2018-214367
 |subject=Immunology;General Biochemistry, Genetics and Molecular Biology;Immunology and Allergy;Rheumatology|+sep=;
 |issn=0003-4967;1468-2060|+sep=;
 |retrieved-from=https://dx.doi.org/
 |retrieved-on=2021-02-25
 |@show=true
}}